Ajanta Pharma
Ajanta Pharma
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return1816%
-
Sales Growth30%
-
Return on Equity41 %
Why Super 50
It has seen a 65-fold growth in market value in 15 years. Its revenues and net profit have grown at a CAGR of 31 percent and 57 percent respectively since 2011. It is a net debt free company that caters to the specialty generics drug market where the scope for growth is immense. It is just about entering the lucrative US market with its products that bodes well for future earnings.
prev
next